This group explores all literacy and advocacy related to biomedical clinical trials. Conversations and events will range across the full spectrum of clinical trial life-cycles from pipeline development to post-trial planning.
Also, there’s a webinar today to discuss 083 results. Details:
The HIV Prevention Trials Network (HPTN) invites you to join a community webinar to learn the primary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that a PrEP regimen containing CAB LA was superior to oral TDF/FTC for the prevention of HIV acquisition among cisgender men and transgender women who have sex with men.
Should cabotegravir be licensed for PrEP in gay men and trans women right away on the basis of HPTN083 results, or wait until HPTN084 gives an answer for cis women? Can we learn something from the F/TAF experience (label for MSM and transwomen and post-marketing commitment to do a trial in cis women)?